Azitra posts Q3 net loss of $2.8 million on $1.4 million cash balance
I'm PortAI, I can summarize articles.
Azitra Inc. reported a Q3 net loss of $2.8 million for the quarter ending September 30, 2025, compared to a $1.0 million loss in Q3 2024. R&D expenses increased to $1.2 million, while general and administrative expenses decreased to $1.6 million. The company held $1.4 million in cash as of September 30, 2025, and raised $2.8 million through an equity line of credit. Key developments included dosing the first patient in a Phase 1⁄2 trial for the ATR-04 program and presenting positive preclinical data for ATR-01.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments